Fumarola C - Search Results

1

Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells.

Digiacomo G, Fumarola C, La Monica S, Bonelli M, Cavazzoni A, Galetti M, Terenziani R, Eltayeb K, Volta F, Zoppi S, Bertolini P, Missale G, Alfieri R, Petronini PG. Digiacomo G, et al. Among authors: fumarola c. Front Oncol. 2024 Dec 6;14:1532291. doi: 10.3389/fonc.2024.1532291. eCollection 2024. Front Oncol. 2024. PMID: 39711960 Free PMC article.

2

Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines.

Fumarola C, Bozza N, Castelli R, Ferlenghi F, Marseglia G, Lodola A, Bonelli M, La Monica S, Cretella D, Alfieri R, Minari R, Galetti M, Tiseo M, Ardizzoni A, Mor M, Petronini PG. Fumarola C, et al. Front Oncol. 2019 Mar 26;9:179. doi: 10.3389/fonc.2019.00179. eCollection 2019. Front Oncol. 2019. PMID: 30972293 Free PMC article.

3

Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines.

Digiacomo G, Fumarola C, La Monica S, Bonelli MA, Cretella D, Alfieri R, Cavazzoni A, Galetti M, Bertolini P, Missale G, Petronini PG. Digiacomo G, et al. Among authors: fumarola c. Front Oncol. 2020 Sep 23;10:563249. doi: 10.3389/fonc.2020.563249. eCollection 2020. Front Oncol. 2020. PMID: 33072590 Free PMC article.

4

CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells.

Digiacomo G, Fumarola C, La Monica S, Bonelli M, Cavazzoni A, Galetti M, Terenziani R, Eltayeb K, Volta F, Zoppi S, Bertolini P, Missale G, Alfieri R, Petronini PG. Digiacomo G, et al. Among authors: fumarola c. Front Oncol. 2022 Jul 22;12:942341. doi: 10.3389/fonc.2022.942341. eCollection 2022. Front Oncol. 2022. PMID: 35936714 Free PMC article.

5

Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion.

La Monica S, Minari R, Cretella D, Bonelli M, Fumarola C, Cavazzoni A, Galetti M, Digiacomo G, Riccardi F, Petronini PG, Tiseo M, Alfieri R. La Monica S, et al. Among authors: fumarola c. Target Oncol. 2019 Oct;14(5):619-626. doi: 10.1007/s11523-019-00669-x. Target Oncol. 2019. PMID: 31502118

6

Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells.

Cretella D, Fumarola C, Bonelli M, Alfieri R, La Monica S, Digiacomo G, Cavazzoni A, Galetti M, Generali D, Petronini PG. Cretella D, et al. Among authors: fumarola c. Sci Rep. 2019 Sep 10;9(1):13014. doi: 10.1038/s41598-019-49484-4. Sci Rep. 2019. PMID: 31506466 Free PMC article.

7

Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells.

Bonelli M, Terenziani R, Zoppi S, Fumarola C, La Monica S, Cretella D, Alfieri R, Cavazzoni A, Digiacomo G, Galetti M, Petronini PG. Bonelli M, et al. Among authors: fumarola c. Int J Mol Sci. 2020 Jul 21;21(14):5165. doi: 10.3390/ijms21145165. Int J Mol Sci. 2020. PMID: 32708306 Free PMC article.

8

Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib.

La Monica S, Fumarola C, Cretella D, Bonelli M, Minari R, Cavazzoni A, Digiacomo G, Galetti M, Volta F, Mancini M, Petronini PG, Tiseo M, Alfieri R. La Monica S, et al. Among authors: fumarola c. Cancers (Basel). 2020 Dec 22;13(1):6. doi: 10.3390/cancers13010006. Cancers (Basel). 2020. PMID: 33374971 Free PMC article.

9

CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells.

Terenziani R, Galetti M, La Monica S, Fumarola C, Zoppi S, Alfieri R, Digiacomo G, Cavazzoni A, Cavallo D, Corradi M, Tiseo M, Petronini PG, Bonelli M. Terenziani R, et al. Among authors: fumarola c. Cancers (Basel). 2022 Nov 30;14(23):5925. doi: 10.3390/cancers14235925. Cancers (Basel). 2022. PMID: 36497412 Free PMC article.

10

Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators.

Volta F, La Monica S, Leonetti A, Gnetti L, Bonelli M, Cavazzoni A, Fumarola C, Galetti M, Eltayeb K, Minari R, Petronini PG, Tiseo M, Alfieri R. Volta F, et al. Among authors: fumarola c. Target Oncol. 2023 Nov;18(6):953-964. doi: 10.1007/s11523-023-01005-0. Epub 2023 Oct 19. Target Oncol. 2023. PMID: 37855989 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

64 results

Search Page

Filters